Table 3.
Most frequently reported suspect product’s active ingredients during the study period (top 20)
| Non-DI reports (N = 3,625,330) | DI reports (N = 247,513) | |||||
|---|---|---|---|---|---|---|
| Product active ingredient | N | % | Product active ingredient | N | % of DI reports | % of all reports |
| Adalimumab | 200,482 | 5.5 | Adalimumab | 19,848 | 8.0 | 9.0 |
| Etanercept | 193,799 | 5.3 | Etanercept | 14,187 | 5.7 | 6.8 |
| Calcium chloride, dextrose, magnesium chloride, sodium chloride, sodium lactate | 87,998 | 2.4 | Naproxen sodium | 5975 | 2.4 | 30.9 |
| Lenalidomide | 77,064 | 2.1 | Pregabalin | 5600 | 2.3 | 13.0 |
| Natalizumab | 58,484 | 1.6 | OnabotulinumtoxinA | 5503 | 2.2 | 41.2 |
| Rivaroxaban | 57,412 | 1.6 | Loratadine | 4397 | 1.8 | 32.5 |
| Rosiglitazone maleate | 54,763 | 1.5 | Sildenafil citrate | 3985 | 1.6 | 26.0 |
| Teriparatide | 53,934 | 1.5 | Gabapentin | 3693 | 1.5 | 18.2 |
| Interferon beta-1a | 52,166 | 1.4 | Fexofenadine hydrochloride | 3462 | 1.4 | 36.8 |
| Dimethyl fumarate | 51,953 | 1.4 | Dalfampridine | 3429 | 1.4 | 14.1 |
| Ribavirin | 51,403 | 1.4 | Buprenorphine | 3419 | 1.4 | 13.2 |
| Ambrisentan | 49,966 | 1.4 | Ibuprofen | 3222 | 1.3 | 13.8 |
| Levonorgestrel | 48,390 | 1.3 | Infliximab | 3187 | 1.3 | 8.4 |
| Denosumab | 38,204 | 1.1 | Polyethylene glycol 3350 | 2614 | 1.1 | 18.4 |
| Pregabalin | 37,473 | 1.0 | Fluticasone propionate, salmeterol xinafoate | 2541 | 1.0 | 12.5 |
| Infliximab | 34,602 | 1.0 | Abatacept | 2531 | 1.0 | 15.8 |
| Peginterferon alfa-2a | 33,640 | 0.9 | Apremilast | 2454 | 1.0 | 10.9 |
| Insulin lispro | 31,554 | 0.9 | Levonorgestrel | 2352 | 1.0 | 4.6 |
| Aspirin | 30,110 | 0.8 | Albuterol sulfate | 2351 | 0.9 | 16.9 |
| Risperidone | 27,266 | 0.8 | Insulin lispro | 2349 | 0.9 | 6.9 |
DI drug ineffective